Influence of simvastatin on aspects of thrombogenesis in CAPD patients

Peritoneal Dialysis International

Volumn 23, Issue 3, 2003, Pages 260-266

  Malyszko, Jolanta ^a   Malyszko, Jacek S ^a   Hryszko, Tomasz ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Endothelium; Extrinsic coagulation pathway; Fibrinolysis; Simvastatin; Thrombogenesis

Indexed keywords

BLOOD CLOTTING FACTOR 10A; FATTY ACID BINDING PROTEIN; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; ARTICLE; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIAGNOSTIC KIT; DRUG DOSE REGIMEN; ENDOTHELIUM INJURY; EUGLOBULIN LYSIS TEST; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY DISEASE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOGENESIS; THROMBOSIS;

EID: 0042386737     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080302300308     Document Type: Article

References (36)

1. Lindner A, Charra B, Sherrad DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290:697-701.
2. Bloembergen WE, Prot FK, Mauger EA, Wolfe RA. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 6:184-91.
3. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1998; 340:115-26.
4. Hackman A, Abe Y, Insull W, Pownall H, Smith L, Dunn K, et al. Levels of soluble adhesion molecules in patients with dyslipidemia. Circulation 1996; 93:1334-8.
5. Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S. Interactions of platelets, macrophages and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998; 31:39-45.
6. Siamopoulos KC, Elisaf MS, Bairaktari HT, Pappas MB, Sferopoulos GD, Nikolakakis NG. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis. Perit Dial Int 1995, 15:342-7.
7. Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y, et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1996; 27:848-54.
8. Bofinger A, Weshuyzen J, Saltissi D, Morgan C, Healy H. Low density lipoprotein subfraction profiles in dialysis patients. Nephrology 1997; 3:169-77.
9. Kawaguchi Y, Kubo H, Yamamoto H, Nakayama K, Shigematsu T, Sakai O. Is atherosclerosis accelerated by CAPD? Perit Dial Int 1996; 16(Suppl 1):S23-30.
10. Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron 1997; 75:125-39.
11. Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J 2000; 139:577-83.
12. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1989; 279:1643-50.
13. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103:2248-53.
14. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 2002; 39:283-90.
15. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Effects of long-term treatment with simvastatin on some hemostatic parameters in CAPD patients. Am J Nephrol 2001; 21:373-8.
16. Malyszko J, Urano T, Knofler R, Taminato A, Yoshimi T, Takada Y, et al. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 1994; 75:569-76.
17. Malyszko J, Malyszko JS, Mysliwiec M, Takada Y, Takada A. Cyclosporine and FK 506 affect platelet function in vitro. Platelets 1995; 6:366-70.
18. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-9.
19. Kowalski E, Kopec M, Niewiarowski S. An evaluation of the euglobulin method for determination of fibrinolysis. J Clin Pathol 1959; 12:215-21.
20. Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S. Interactions of platelets, macrophages and lipoproteins in hypercholesterolemia: anti-atherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998; 31:39-45.
21. Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA reductase inhibitor. Thromb Res 1999; 95: 229-34.
22. Kario K, Matsuo T, Yamada T, Matsuo M. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 1994; 71:275-9.
23. Di Garbo V, Cordova R, Avellone G. Increased thrombin generation and complement activation in patients with type IIa hyperlipoproteinemia: effects of simvastatin treatment. Current Therapy Research 1997; 58:706-23.
24. Essig M, Vrtovsnik F, Ngyuen G, Sraer JD, Friedlander G. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol 1998; 9:1377-88.
25. Yorioka N, Masaki T, Ito T, Kushikata S, Nishida Y, Taniguchi Y, et al. Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis. Int J Artif Organs 1998; 23:27-32.
26. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
27. Romano M, Mezzetti A, Maruli C, Ciabattoni G, Febo F, Di Ienno S, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients. J Invest Med 2000; 48:183-9.
28. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104:376-9.
29. Guijarro C, Keane WF. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Miner Electrolyte Metab 1996; 22:147-52.
30. Blann AD, Gurney D, Hughes E, Buggins P, Silverman SH, Lip GYH. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. Am J Cardiol 2001; 88:89-92.
31. Asberg A, Hartmann A, Fjeldsa E, Holdaas H. Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol Dial Transplant 2001; 12:1920-4.
32. Ambrosi P, Aillaud MF, Habib G, Kreitman B, Metras D, Luccioni R, et al. Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients. Thromb Haemost 2000; 83:46-8.
33. Blann AD, Belgore FM, Constans J, Conri C, Lip GYH. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 2001; 87:1160-3.
34. Dvorakova J, Hyanek J, Dubska L, Taborsky L, Pejznochova H. Effect of pravastatin on plasma concentrations of homocysteine in primary hypercholesterolemia. Atherosclerosis 2001; 2:94.
35. Malyszko J, Malyszko JS, Mysliwiec M. Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis. Perit Dial Int 2001; 21:158-65.
36. Kobayashi M, Yorioka N, Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron 1997; 76:56-61.